REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
20/07/2026
Voltar para busca
Dado oficial do USPTO
EQUGLEV
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
20/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
09/11/2020
Data de registro
20/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/07/2021
Última transação
20/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
CH
Examinador
PINO, BRIAN
Unidade examinadora
M50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sandoz AG
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
CHLD
CHANGE OF OWNER RECEIVED FROM IB
19/01/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/01/2022
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
19/11/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
19/11/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
20/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
20/07/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/05/2021
PUBO
PUBLISHED FOR OPPOSITION
04/05/2021
GPNX
NOTIFICATION PROCESSED BY IB
03/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/04/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2021
RFNT
REFUSAL PROCESSED BY IB
29/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/03/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/03/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/03/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/03/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/03/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/03/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/03/2021
RFRR
REFUSAL PROCESSED BY MPU
05/03/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/03/2021
CNRT
NON-FINAL ACTION WRITTEN
01/03/2021
DOCK
ASSIGNED TO EXAMINER
23/02/2021
MAFR
APPLICATION FILING RECEIPT MAILED
15/01/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/01/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
09/01/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
31/12/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EQUGLEV ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.